Japanese
close

F-Term-List

4C086 PHARMACEUTICALS CONTAINING OTHER ORGANIC AND INORGANIC COMPOUNDS
A61K31/33 -33/44
A61K31/33-33/44 AA AA00
TYPE OF INVENTION 		AA01 AA02 AA03 AA04 AA10
. Medicinal use described in the claims . Use of experimental data of medicinal use or evidence of pharmacological effects . Chemical substance described in the claims . Synthesis methods described in the claims . Others
BA BA00
SINGLE HETEROCYCLIC COMPOUND CONTAINING ONLY AN OXYGEN ATOM IN A RING 		BA01 BA02 BA03 BA04 BA05 BA06 BA07 BA08 BA09 BA10
. containing only one oxygen atom in a ring . . in four or less membered ring . . in five membered ring . . . Nitrofuran . . . condensed with carbocyclic ring . . . . Benzofuran . . containing one carbon atom in a six membered ring . . . condensed with carbocyclic rings . . . . Tocopherol e.g. vitamin E . . containing one oxygen atom in seven or more membered ring
BA11 BA12 BA13 BA14 BA15 BA16 BA17 BA18 BA19 BA20
. containing only two or more oxygen atoms in a ring . . Five-membered ring containing two or more oxygen atoms . . . condensed with carbocyclic ring . . Six-membered ring containing two or more oxygen atoms . . . condensed with carbocyclic ring . . Seven- or more membered ring containing two or more oxygen atoms . Lactones . . Ascorbic acid i.e. vitamin C; Salts thereof . . Coumarin . Others
BB BB00
SINGLE HETEROCYCLIC COMPOUND CONTAINING SULFUR ATOM IN A RING 		BB01 BB02 BB03 BB04 BB05 BB10
. containing only one sulfur atom in a ring . . Five-membered ring containing one sulfur atom . . . condensed with carbocyclic ring . containing two or more sulfur atoms in the same ring . containing oxygen and sulfur atoms in the same ring . Others
BC BC00
SINGLE HETEROCYCLIC COMPOUND CONTAINING NITROGEN ATOM IN A RING, OR CONTAINING SELENIUM, TELLURIUM, OR HALOGEN ATOM IN A RING 		BC01 BC02 BC03 BC04 BC05 BC06 BC07 BC08 BC09 BC10
. containing one nitrogen atom in a ring . . Four- or less membered ring containing only one nitrogen atom . . . Azetidinone . . in five membered ring containing one nitrogen atom alone. . . . Pyrrole . . . Pyrroline . . . Pyrrolidine . . . . Oxygen atoms being directly and doubly bound to ring . . . . Imino groups being directly and doubly bound to ring . . . condensed with carbocyclic ring
BC11 BC12 BC13 BC14 BC15 BC16 BC17 BC18 BC19 BC20
. . . . Phthalimido . . . . Carbazole . . . . Indole . . . . . Indole alkanecarboxylic acid compounds . . . . . . Indometacin; Salts thereof excluding derivatives . . in six membered ring containing one nitrogen atom alone. . . . Pyridine . . . . Vitamin B6 or pyridoxine . . . . Nicotinic acid . . . . Nicotine
BC21 BC22 BC23 BC24 BC25 BC26 BC27 BC28 BC29 BC30
. . . Piperidine . . . . Cycloheximide . . . 14-dihydropyridine . . . . 35-dicarboxylic acid and derivatives . . . . . Symmetrical diester . . . . . Asymmetrical diester . . . condensed with carbocyclic ring . . . . Quinoline or hydrogenated quinoline . . . . . Carboxyl group carboalkoxy group or carbamoyl group bound directly to a heterocyclic ring . . . . Isoquinoline or hydrogenated isoquinoline
BC31 BC32 BC33 BC34 BC35 BC36 BC37 BC38 BC39 BC40
. . in seven membered ring containing one nitrogen atom alone . . . condensed with carbocyclic ring . . in eight or more membered ring containing one nitrogen atom alone . containing only two nitrogen atoms in a ring . . five-membered ring containing only two nitrogen atoms . . . containing nitrogen atoms in positions 1 and 2 . . . . condensed with carbocyclic ring . . . containing nitrogen atoms in positions 1 and 3 . . . . condensed with carbocyclic ring . . six-membered ring containing only two nitrogen atoms
BC41 BC42 BC43 BC44 BC45 BC46 BC47 BC48 BC49 BC50
. . . containing nitrogen atoms in positions 1 and 2 . . . containing nitrogen atoms in positions 1 and 3 . . . . Uracil . . . . Barbituric acid . . . . condensed with carbocyclic ring . . . . . Quinazoline or hydrogenated quinazoline . . . containing nitrogen atoms in positions 1 and 4 . . . . Pyrazine . . . . Hydrogenated pyrazine ring . . . . . Piperazine
BC51 BC52 BC53 BC54 BC55 BC56 BC57 BC58 BC59 BC60
. . . . condensed with carbocyclic ring . . . . . Quinoxaline or hydrogenated quinoxaline . . Seven-membered ring containing only two nitrogen atoms . . . containing nitrogen atoms in positions 1 and 4 . . . . condensed with carbocyclic ring . . . . . Benzodiazepine or hydrogenated benzodiazepine . . Eight- or more membered ring containing only two nitrogen atoms . containing three or more nitrogen atoms only in a ring . . Five-membered ring containing only three nitrogen atoms . . . Triazole or hydrogenated triazole
BC61 BC62 BC63 BC64 BC65 BC66 BC67 BC68 BC69 BC70
. . . . condensed with carbocyclic ring . . . Tetrazole or hydrogenated tetrazole . . Six-membered ring containing only three or more nitrogen atoms . . . Triazine or hydrogenated triazine . containing at least one oxygen atom and one nitrogen atom in a ring . . Five-membered ring containing an oxygen atom and a nitrogen atom . . . containing oxygen and nitrogen atoms in positions 1 and 2 . . . . condensed with carbocyclic ring . . . containing oxygen and nitrogen atoms in positions 1 and 3 . . . . condensed with carbocyclic ring
BC71 BC72 BC73 BC74 BC75 BC76 BC77 BC78 BC79 BC80
. . . Oxadiazole or hydrogenated oxadiazole . . Six-membered ring containing oxygen and nitrogen atoms . . . containing oxygen and nitrogen atoms in positions 1 and 4 . . . . condensed with carbocyclic ring . . Seven-membered ring containing oxygen and nitrogen atoms . . Eight- or more membered ring containing oxygen and nitrogen atoms . containing at least one sulfur atom and one nitrogen atom in a ring . . Five-membered ring containing sulfur and nitrogen atoms . . . containing sulfur and nitrogen atoms in positions 1 and 2 . . . . condensed with carbocyclic ring
BC81 BC82 BC83 BC84 BC85 BC86 BC87 BC88 BC89 BC90
. . . . . Oxygen atom bound to a sulfur atom in a heterocyclic ring . . . containing sulfur and nitrogen atoms in positions 1 and 3 . . . . Thiamine i.e. vitamin B1 . . . . condensed with carbocyclic ring . . . Thiadiazole or hydrogenated thiadiazole . . . . 1 2 4-thiadiazole . . Six-membered ring containing sulfur and nitrogen atoms . . . containing sulfur and nitrogen atoms in positions 1 and 4 . . . condensed with carbocyclic ring . . . . Pyroxycam; Salts thereof
BC91 BC92 BC93 BC94 BC95 BC99
. . Seven-membered ring containing sulfur and nitrogen atoms . . . condensed with carbocyclic ring . . Eight- or more membered ring containing sulfur and nitrogen atoms . containing oxygen sulfur and nitrogen atoms in a ring . containing selenium tellurium and halogen atoms in a ring . Others
CA CA00
CONDENSED HETEROCYCLIC COMPOUND CONTAINING NO NITROGEN ATOM IN A RING 		CA01 CA02 CA03 CA04 CA05 CA10
. containing only oxygen atom in a ring . . Polyether-based compound . . Macrolide-based compound . containing only sulfur atom in a ring . containing at least one oxygen atom and one sulfur atom in a ring . Others
CB CB00
CONDENSED HETEROCYCLIC COMPOUND CONTAINING NITROGEN ATOM IN A RING 		CB01 CB02 CB03 CB04 CB05 CB06 CB07 CB08 CB09 CB10
. containing only nitrogen atom in a ring . . Four- or less membered heterocyclic ring containing only nitrogen atom . . containing two or more five-membered heterocyclic rings containing only nitrogen atoms . . . Porphyrin compound . . containing five- and six-membered heterocyclic rings containing only nitrogen atoms . . . Pyrazolo pyrimidine . . . Purine . . . Triazolo pyrimidine . . containing two six-membered heterocyclic rings containing only nitrogen atoms . . . Pyrimido pyrimidine
CB11 CB12 CB13 CB14 CB15 CB16 CB17 CB18 CB19 CB20
. . containing seven-membered ring containing only nitrogen atom . . . Imidazo diazepine . . . Triazolo diazepine . . containing eight- or more membered heterocyclic ring containing only nitrogen atom . . 8-azabicyclo [3.2.1] octane . . 9-azabicyclo [3.3.1] nonane . . Quinuclidine or isoquinuclidine . . Quinolizine . . Benzoindolo [2 3-a]quinolizine . . Indolo [4 3 -f g]quinoline
CB21 CB22 CB23 CB24 CB25 CB26 CB27 CB28 CB29 CB30
. . Indolo (3 21 )pyrido (3 2 1) (1 5) naphthyridine . containing at least one oxygen atom and one nitrogen atom in a ring . . Imino ethano phenanthro-furan . . Strychnidine . . Rifamycin compounds . containing at least one sulfur atom and one nitrogen atom in a ring . . Five-membered heterocyclic ring containing sulfur and nitrogen atoms in a ring . . . Biotin . . Six-membered heterocyclic ring containing sulfur and nitrogen atoms in a ring . . Seven-membered heterocyclic ring containing sulfur and nitrogen atoms in a ring
CB31 CB40
. containing oxygen sulfur and nitrogen atoms in a ring . Others
CC CC00
BETA-LACTAM BASED CONDENSED HETEROCYCLIC COMPOUND 		CC01 CC02 CC03 CC04 CC05 CC06 CC07 CC08 CC09 CC10
. Penams . . having nitrogen atom directly attached in position 6 and carbon atom attached in position 2 which has three bond to hetero atoms with at most one bond to halogen (specifically carbon atom attached in position 2 is derived from carboxylic acid) . . . with unsubstituted amino group attached in position 6 . . . with an acylated amino group attached in position 6 . . with a nitrogen atom not attached in position 6 directly . . containing double bond between 2- and 3-positions . Oxapenams . Carbapenams . Cephems . . with an acylated amino group attached in position 7
CC11 CC12 CC13 CC14 CC15 CC16 CC17 CC18 CC19 CC20
. . . with an acylated amino group derived from alpha-oxyiminoacetic acid . . . . containing thiazole . . containing a substituted hydrocarbon group at position 3 . . . containing methylene groups substituted by oxygen atoms . . . containing methylene groups substituted by sulfur atoms . . . containing methylene groups substituted by nitrogen atoms . . . containing vinylene groups: - CH= CH- . Oxacephems . Carbacephems . Azacephems
CC30
. Others
DA DA00
COMPOUND CHARACTERISED BY STRUCTURAL PART OF ACTIVITY EXPRESSION 		DA01 DA02 DA03 DA04 DA05 DA06 DA07 DA08 DA09 DA10
. Prostaglandins . . with a hydroxy group directly bound to cyclopentane ring . . with carbonyl group in cyclopentane ring . . containing sulfur atom . . containing heterocyclic ring . . . containing furan ring . . . containing thiophene ring . Cyclopenta[a]hydrophenanthrene containing ring-modified steroid . . with beta-17-position not substituted by carbon atom . . with beta-17-position substituted by chain of two carbon atoms
DA11 DA12 DA13 DA14 DA15 DA16 DA17 DA18 DA19 DA20
. . with beta-17-position substituted by chain of three or more carbon atoms . . containing heterocyclic ring . . . containing lactone ring . 9 10-seco-cyclopenta[a]hydrophenanthrene . . containing hydroxy group in alpha-1-position . . containing hydroxy group in position 24 or 25 . Salicylic acid . . containing heterocyclic ring . containing para-N-benzene- sulfonyl-N-groups . . containing heterocyclic ring
DA21 DA22 DA23 DA24 DA25 DA26 DA27 DA28 DA29 DA30
. Sulfonylureas . . containing heterocyclic ring . having ring system comprising three condensed rings in which amino group or amino alkylene group attach to centre ring thereof . . containing two benzene rings . . . centre ring consisting of six membered ring . . . . centre ring containing one nitrogen atom and one sulfur atom . . . centre ring consisting of seven-membered ring . . . . centre ring containing only two nitrogen atoms . Tetracycline based compound . Azo diazo azoxy azido or diazo-amino compound
DA31 DA32 DA33 DA34 DA35 DA36 DA37 DA38 DA39 DA40
. Organic heavy metal compound . . Platinum containing compound . . Germanium containing compound . Organic phosphorus compounds . . having ring structure containing phosphorus as ring member . . containing heterocyclic ring excluding compounds containing phosphorus as ring member . . . containing oxygen as ring member . . . containing nitrogen as ring member . . . . Cobalamin . . Amine salt of phosphoric acid
DA41 DA42 DA43 DA44 DA45 DA50
. . . Glycerophospholipids . . . Sphingophospholipids . Organic boron compounds . Organic silicon compounds . . Low molecular weight organopolysiloxane . Others
EA EA00
CARBOHYDRATE OR SACCHARIDE 		EA01 EA02 EA03 EA04 EA05 EA06 EA07 EA08 EA09 EA10
. Monosaccharides disaccharides or oligosaccharides with up to six saccharide radicals . . Saccharide containing nitrogen halogen sulfur selenium or tellurium . . esterified saccharides . . with hydrocarbon groups substituted hydrocarbon groups or heterocyclic groups directly bound to hetero atoms of saccharide radicals . . . with acyclic groups not substituted by cyclic groups directly bound to hetero atom of saccharide radicals . . . . Sphingoglycolipid . . . with acyclic groups substituted by cyclic groups directly bound to hetero atoms of saccharide radicals . . . with carbon ring alone directly bound to hetero atom of saccharide radicals . . . . Cyclohexane ring . . . . condensed carbon ring system containing three or more rings
EA11 EA12 EA13 EA14 EA15 EA16 EA17 EA18 EA19 EA20
. . . with heterocyclic rings directly bound to hetero atom of saccharide radicals. . . . . Macrolide glycoside . . . . . of fourteen membered ring . . . . . of sixteen membered ring . . . . . Polyene-based macrolide . . Nucleoside nucleotide or nucleic acid . . . Heterocyclic ring being pyrimidine ring . . . Heterocyclic ring being purine ring . . containing steroid skeleton . Polysaccharides i.e. compounds with seven or more saccharide radicals
EA21 EA22 EA23 EA24 EA25 EA26 EA27 EA28 EA30
. . Ether or ester . . containing amino group . . . Chitin or chitosan . . containing acid group . . . containing carboxyl group . . . containing sulfonic acid group . . . . Heparin . with unspecified or unknown structure . Others
FA FA00
SYNTHETIC POLYMERIC SUBSTANCE 		FA01 FA02 FA03 FA04 FA05 FA06 FA07 FA10
. Hydrocarbon polymers or polymers containing halogen . Polymers containing oxygen . Polymers containing nitrogen . Polymers containing sulfur . Polymers containing hetero atoms other than halogen oxygen nitrogen or sulfur . Polymers bound to the active ingredient of low molecular weight compound . Polymers having ion-exchange capability . Others
GA GA00
CHARACTERISTIC CHEMICAL STRUCTURE OF ORGANIC ACTIVE INGREDIENT 		GA01 GA02 GA03 GA04 GA05 GA06 GA07 GA08 GA09 GA10
. Compounds containing a plurality of single heterocyclic rings . . heterocyclic ring containing only oxygen atoms in ring . . heterocyclic ring containing sulfur atoms in ring . . . heterocyclic ring containing only sulfur atoms in ring . . . heterocyclic ring containing oxygen and sulfur atoms in the same ring . . heterocyclic ring containing nitrogens atom in ring . . . heterocyclic ring containing only nitrogen atom in ring . . . . Pyridine ring . . . heterocyclic ring containing oxygen and nitrogen atoms in the same ring . . . heterocyclic ring containing nitrogen and sulfur atoms in the same ring
GA11 GA12 GA13 GA14 GA15 GA16 GA17 GA20
. . . heterocyclic ring containing oxygen sulfur and nitrogen atoms in the same ring . . . Heterocyclic ring consisting of cyclic amino group with only hydrogen atoms directly bound to ring carbon atoms . Salt specifically described in the claims . . All structural elements of a salt are organic compounds . Crystal forms specifically described in the claims . Optical isomers specifically described in the scope of claims . extracted and generated from natural products . Others
HA HA00
CHEMICAL STRUCTURE OF INORGANIC ACTIVE INGREDIENT 		HA01 HA02 HA03 HA04 HA05 HA06 HA07 HA08 HA09 HA10
. Elements of the 1st Group of the Periodic System . . Alkali metal . Elements of the 2nd Group of the Periodic System . . Alkaline earth metal . Elements of the 3rd Group of the Periodic System . Elements of the 4th Group of the Periodic System . Elements of the 5th Group of the Periodic System . Elements of the 6th Group of the Periodic System . Elements of the 7th Group of the Periodic System . Elements of the 8th Group of the Periodic System
HA11 HA12 HA13 HA14 HA15 HA16 HA17 HA18 HA19 HA20
. . Iron . . Platinum . Elements of the 0th Group of the Periodic System . Acid or acid residue excluding organic acid per se . . Inorganic acid or inorganic acid residue . . . Carbonic acid bicarbonic acid; or acid residue thereof . . . Sulfur containing acid; or acid residue thereof . . . Silicon containing acid; or acid residue thereof . . . Phosphorus containing acid; or acid residue thereof . . Organic acid residue; or organic base residue
HA21 HA22 HA23 HA24 HA25 HA26 HA27 HA28 HA30
. Oxide . Peroxide . Hydroxide . Halide including hydrohalogenic acid . Sulfide including hydrosulfuric acid . Ammonium or ammonia-containing components . Mixture of natural inorganic ingredients . Complexes chelates coordination compounds or double salts . Others
MA MA00
COMPOUNDING AGENT, DOSAGE FORM, OR APPLICABLE SITE 		MA01 MA02 MA03 MA04 MA05 MA06 MA07 MA08 MA09 MA10
. with one compounding ingredient described in the scope of claims . with two compounding ingredients described in the scope of claims . with three or more compounding ingredients described in the scope of claims . only medically effective ingredients described in the scope of claims . medically effective and inactive ingredients described in the scope of claims . Unidentified ingredients whether medically effective or non-active ingredients described in the scope of claims . Containing ingredients not covered by viewpoints BA to HA . . Alcohol ether or ketone . . Carboxylic acid or its ester . . Amine or amide
MA11 MA12 MA13 MA16 MA17
. Dosage form . . Gaseous . . . Aerosol or foamed agents . . Liquid . . . Solutions e.g. aqueous solution or non-aqueous solution
MA21 MA22 MA23 MA24 MA27 MA28
. . . Liquid dispersion agents . . . . Emulsion . . . . Syrup or suspension . . . . Ribosome . . Semi-solids . . . Creams pastes or ointments
MA31 MA32 MA34 MA35 MA36 MA37 MA38
. . . Suppositories or bougies . . . Pasting agents . . Solids . . . Pills or buccals . . . Pellets . . . Capsules . . . . Micro-capsules
MA41 MA43 MA44 MA47
. . . Granular agents . . . Powdered agents . . . . freeze-dried powder . . . Gums
MA51 MA52 MA55 MA56 MA57 MA58 MA59 MA60
. Application sites . . Oral . . Non-oral . . . Body cavity or mucous membrane . . . . Oral cavity . . . . Eyes . . . . Nasal cavity . . . . Rectum
MA63 MA65 MA66 MA67 MA70
. . . Skin or skin exterior . . . Blood vessel or tissue interior . . . . Injection infusion or intravenous drip . . . . Internal embedding . Others (*)
NA NA00
PURPOSE OR EFFECT OF COMPOUND PER SE, COMPOUNDING, OR FORMULATION 		NA01 NA02 NA03 NA04 NA05 NA06 NA07 NA08 NA09 NA10
. Virus attenuation . Solubilisation . Stabilisation . Timing adjustment . Improvement of work reinforcement or selectivity . Reduction of side reactions . Toxicity reduction . Painlessness . Correction of taste or odour . Change of dose mode
NA11 NA12 NA13 NA14 NA15 NA20
. Absorption improvement . Controlled or sustained release . Drug delivery system (DDS) . Expression of new medicine effects . Pro-drugs . Others (*)
ZA ZA00
MEDICINAL USE AND TARGET ORGAN 		ZA01 ZA02 ZA03 ZA04 ZA05 ZA06 ZA07 ZA08
. Pharmaceuticals working on nervous system . . Central nervous system . . . Central nervous system inhibitors . . . . General anaesthetics . . . . Hypnotics or sedatives . . . . Anti-epilepsy drugs . . . . Antipyretic agents . . . . Pain-killers
ZA11 ZA12 ZA14 ZA15 ZA16 ZA18 ZA20
. . . Central nervous stimulants . . . . Anti-depression drugs . . . Anti-motion-sickness drugs . . . Drugs for improvement of brain function . . . . Drugs for Alzheimer's disease . . . Anti psychoneurosis agents . . Medicine for peripheral nerves
ZA21 ZA22 ZA23 ZA24 ZA25 ZA26 ZA27 ZA28 ZA29 ZA30
. . . Sensory nerve drugs . . . Motor nerve drugs . . . . Skeletal muscle relaxantss . . . Autonomic nerve drugs . . . . Sympathetic nerve stimulants . . . . Sympathetic nerve inhibitors . . . . Parasympathetic nerve stimulants . . . . Parasympathetic nerve depressants . . . . Anti-spasmodics . . . . Diaphoretic or stoppage of perspiration agent
ZA31 ZA32 ZA33 ZA34 ZA36 ZA37 ZA38 ZA39 ZA40
. Medicine having effects on each organs . . Drugs for sensory organs . . . Ophthalmic agents . . . Otorhinology drugs . . Drugs for circulatory organs . . . Myocardium stimulants . . . Myocardium inhibitors . . . Blood vessel vasodilators . . . . Coronary blood vessel vasodilators
ZA41 ZA42 ZA43 ZA44 ZA45
. . . Blood vessel vasoconstrictors . . . Blood pressure hypotensive drugs . . . Vasopressors . . . Blood vessel reinforcing agents . . . Drugs for treating arteriosclerosis
ZA51 ZA52 ZA53 ZA54 ZA55 ZA59 ZA60
. . Medicine for hematogenous organs bone marrow blood or humour . . . Substitute blood . . . Haemostatic and blood coagulation drugs . . . Anti-blood coagulation drugs and thrombolytic agents . . . Anti-anemia drugs . . Medicines for respiratory organs . . . Breathing accelerators
ZA61 ZA62 ZA63 ZA66 ZA67 ZA68 ZA69 ZA70
. . . Bronchus vasodilators . . . Antitussives . . . Phlegm remover . . Medicines for digestive organs . . . Dentistry oral cavity drugs . . . Digestive ulcer drugs . . . Peptic digestive drugs . . . Anti-obesity drugs
ZA71 ZA72 ZA73 ZA75 ZA76 ZA77
. . . Sedative for vomitory and vomitous drugs . . . Purgative drugs . . . Intestinal regulators . . . Medicine for liver or bile duct disorders . . . . Biliary drugs . . . . Litholytics
ZA81 ZA82 ZA83 ZA84 ZA85 ZA86 ZA89 ZA90
. . Medicine for urinogenital organs or anus . . . Urine vessel bactericide . . . Diuretics . . . Anti-diuretics . . . Womb contractile drugs . . . Birth control pills . . Outer skin medicine . . . Sanitiser for outer skin
ZA91 ZA92 ZA94 ZA96 ZA97
. . . Skin softener . . . Medicine for head skin or hair . . Medicine for the muscular system . . Medicine for the skeletal system . . . Medicine for osteoporosis
ZB ZB00
MEDICINAL USE OR BIOLOGICAL DEFENCE 		ZB01 ZB02 ZB03 ZB05 ZB07 ZB08 ZB09
. Pharmaceuticals specified by their effects for biophylactic mechanisms. . . Medicine for cellular immunity system . . . Interferon-inducing agents . . Drugs for humoral immune mechanisms i.e. antibody production . . Medicine for immunity adjustments . . Immunity inhibitors . . Immunity accelerators
ZB11 ZB13 ZB15
. . Inflammation drugs . . Anti-allergic drugs . . Anti-rheumatic drugs
ZB21 ZB22 ZB26 ZB27
. Pharmaceuticals having effects on tissue cellular functions . . Drugs for activating cells . . Medicine for tumours . . . Anti-leukaemia medicine
ZB31 ZB32 ZB33 ZB35 ZB37 ZB38 ZB39
. pharmaceuticals having effects on pathogenic organisms . . Medicine for pathogenic microorganisms . . . Anti-viral drugs . . . Antibacterial drugs . . drugs for parasites . . . Anti-protozoan drugs . . . Vermicides
ZC ZC00
MEDICINAL USE, FUNCTION, MECHANISM, TARGET, OR OTHERS 		ZC01 ZC02 ZC03 ZC04 ZC06 ZC08 ZC10
. Pharmaceuticals specified based on the effects on vital functions . . In vivo physiologically active substance-like agents . . . Hormone-like drugs . . . . Pituitary hormone-like drugs . . . . Thyroid parathyroid hormone-like drugs . . . . Paranephros hormone-like drugs . . . . Male hormone-like drugs
ZC11 ZC12 ZC13 ZC14 ZC16 ZC17 ZC19 ZC20
. . . . Female hormone-like drugs . . . Prostaglandins-like drugs . . . Antihistamins . . . Antiserotonin agents . . . Bradykinin-like drugs . . . Angiotensin-like drugs . . . Enzyme activators i.e. agents for activating enzyme activity . . . Enzyme inhibitors
ZC21 ZC22 ZC23 ZC24 ZC25 ZC26 ZC28 ZC29
. . Drugs for metabolic pathways . . . Vitamin-like agents . . . . Vitamin A- or D-like agents . . . . Vitamin B-like agents . . . . . Vitamin B1-like agents . . . . . Vitamin B2-like agents . . . . Vitamin C- or P-like agents . . . . Vitamin E- or K-like agents
ZC31 ZC33 ZC35 ZC37 ZC39
. . . Agents for uric acid metabolic pathway . . . Lipid metabolic system drugs . . . Carbohydrate metabolic system drugs . . . Detoxicants . . . Medicine for habit-forming toxication
ZC41 ZC42 ZC43 ZC44 ZC45 ZC48 ZC50
. Pharmaceuticals specified by their functions and mechanisms . . Receptor antagonists (*) . . . Beta blocker . . . Histamine H2 blocker . . . Histamine H1 blocker . . Anti-platelet activation factors (PAF) medicine . . Calcium antagonists
ZC51 ZC52 ZC54 ZC55
. Pharmaceuticals specified by treatment subjects . . Drugs for geriatric disease . . specified medicines by symptoms or names of diseases (*) . . . Drugs for acquired immune deficiency syndrome (AIDS)
ZC61 ZC62 ZC63 ZC64 ZC65
. . Medicine for animals . . . Udder-inflammation drugs . . . Milk-inducing drugs . . . Drugs for coccidiosis . . . Drugs for poikilothermal animals
ZC71 ZC72 ZC75 ZC78 ZC80
. Medicine related to physical therapy . . Medicine for moxibusion therapy . Synergistic agents . Analysis and detection reagents . Others or unidentified (*)
TOP